##  [Regulatory Perspective of Complementary Medicines in Australia](/index%2ephp/webinars/regulatory-perspective-of-complementary-medicines-in-australia) 

<a>Pharmaceuticals</a>



<a>Past Webinar</a>



## **Regulatory Perspective of Complementary Medicines in Australia**

**The webinar was successfully concluded on**

  **Aug 26, 2021.**

[Download Webinar](javascript:void(0))





We are elated to see your interest in Freyr’s Webinar Series (FWS). The webinar on, **‘Regulatory Perspective of Complementary Medicines in Australia’** was successfully concluded on Aug 26, 2021. Here is an archived version for your kind perusal.

#### What Was It All About?

In brief, during the webinar our in-house Regulatory experts – Kamalakar Deevi and Malgorzata Wojciechowska shared their inputs thoroughly on:

- Complementary Medicines Regulatory Structure in Australia
- Launch of Complementary Medicines Through Listing (L-process) or Registration (R- process)
- Good Manufacturing Practices (GMP) Requirements for Complementary Medicines
- Permissible Ingredients and TGA Assessed Claims
- Information for Sponsors to Market Complementary Medicines in Australia

As a continuous practice, Freyr intends to conduct more informative webinar sessions related to Regulatory aspects of Life Sciences. We presume that you would like to be a part of all our upcoming sessions. If yes, let us have an opportunity to inform you about our next session.